Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
518 hedge funds and large institutions have $30.2B invested in Alexion Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 192 increasing their positions, 210 reducing their positions, and 70 closing their positions.
23% more call options, than puts
Call options by funds: $198M | Put options by funds: $161M
9% less repeat investments, than reductions
Existing positions increased: 192 | Existing positions reduced: 210
5% less funds holding
Funds holding: 547 → 518 (-29)
29% less capital invested
Capital invested by funds: $42.4B → $30.2B (-$12.2B)
33% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 70
33% less funds holding in top 10
Funds holding in top 10: 21 → 14 (-7)
Top Buyers
| 1 |
Royal London Asset Management
United Kingdom
|
+$1.11B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$274M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$138M |
| 4 |
ClearBridge Investments
New York
|
+$83.3M |
| 5 |
Millennium Management
New York
|
+$76.9M |
Top Sellers
| 1 |
Wells Fargo
San Francisco,
California
|
-$199M |
| 2 |
Sands Capital Management
Arlington,
Virginia
|
-$124M |
| 3 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$94.2M |
| 4 |
Bank of New York Mellon
New York
|
-$81.2M |
| 5 |
Goldman Sachs
New York
|
-$62.8M |
ALXN Hedge Fund Activity: Q1 2016 in Review
518 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q1 2016, worth a combined $30.2B — down 29% from $42.4B a quarter earlier.
Sellers outnumbered buyers: 70 funds closed out of ALXN and 47 opened new positions — a net loss of 23 holders — while 210 trimmed existing stakes and 192 added.
The largest buyer was Royal London Asset Management, adding an estimated $1.11B. The largest seller was Wells Fargo, cutting an estimated $199M.
- 518 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q1 2016, down from 547 in Q4 2015.
- Funds reported $30.2B of Alexion Pharmaceuticals stock for Q1 2016, down 29% quarter-over-quarter.
- 47 funds opened new Alexion Pharmaceuticals positions in Q1 2016 and 70 closed out, a net change of -23 holders.
- The largest Alexion Pharmaceuticals buyer in Q1 2016 was Royal London Asset Management, an estimated $1.11B added.
- The largest Alexion Pharmaceuticals seller in Q1 2016 was Wells Fargo, an estimated $199M sold.
Based on aggregated 13F filings for Q1 2016.